What’s Trending?

Shrekli hit with $64.6M verdict, lifetime pharma ban in antitrust case esagonowsky Fri, 01/14/2022 - 16:34 [...]
Fri, Jan 14, 2022
Source FiercePharma
Pfizer's Cibinqo snags FDA approval to challenge Sanofi and Regeneron's Dupixent in eczema esagonowsky Fri, 01/14/2022 - 15:56 [...]
Fri, Jan 14, 2022
Source FiercePharma
Novo Nordisk comes out clean in $1.8B investor lawsuit alleging insulin misdirection fkansteiner Fri, 01/14/2022 - 13:21 [...]
Fri, Jan 14, 2022
Source FiercePharma
Emergent BioSolutions founder El-Hibri bids adieu after CDMO's turbulent 2021 fkansteiner Fri, 01/14/2022 - 11:48 [...]
Fri, Jan 14, 2022
Source FiercePharma
Vir Biotech has launched a new antibody research initiative, expanding its partnership with the Bill & Melinda Gates Foundation [...]
Fri, Jan 14, 2022
Source PharmaTimes
Djokovic drama causes a racket: so how would the UK respond? [...]
Fri, Jan 14, 2022
Source PharmaTimes
A research team led by Prof. Stephan Ludwig, a virologist at the Institute of Virology at the University of M√ľnster, has found a new dual attack mode of action while working on the development of a drug candidate against SARS-CoV-2 infections. This could constitute the basis for a broadly effective [...]
Fri, Jan 14, 2022
Source WorldPharmaNews
GlaxoSmithKline
GlaxoSmithKline plc (LSE/NYSE: GSK) and Vir Biotechnology, Inc. (Nasdaq: VIR) announced that the US Government will purchase an additional 600,000 doses of sotrovimab, an investigational monoclonal antibody for the early treatment of COVID-19, enabling further nationwide access to sotrovimab for patients. [...]
Fri, Jan 14, 2022
Source WorldPharmaNews
AstraZeneca (AZ) has reported preliminary data from a trial it conducted on its COVID-19 booster shot, Vaxzevria. [...]
Thu, Jan 13, 2022
Source PharmaTimes
Despite diagnosis and treatment options improving for the rare kidney condition, further action is urgently required. [...]
Thu, Jan 13, 2022
Source PharmaTimes
AstraZeneca
Positive results from a preliminary analysis of an ongoing safety and immunogenicity trial (D7220C00001) showed that Vaxzevria (ChAdOx1-S [Recombinant]), when given as a third dose booster, increased the immune response to Beta, Delta, Alpha and Gamma SARS-CoV-2 variants, while a separate analysis of samples from the trial showed increased antibody [...]
Thu, Jan 13, 2022
Source WorldPharmaNews
Novartis
Novartis and Molecular Partners announced that Part A of the EMPATHY clinical trial(1) that compared single intravenous doses of ensovibep, a DARPin antiviral therapeutic candidate vs. placebo to treat COVID-19, met the primary endpoint of viral load reduction over eight days. The two secondary endpoints also showed clinically meaningful benefit [...]
Wed, Jan 12, 2022
Source WorldPharmaNews
Sponsors submitting pediatric study plans should consider whether a product affects adults and children similarly when choosing an approach, the FDA says. [...]
Fri, Jan 16, 2015
Source FDANews